These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29299119)

  • 1. Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.
    Hescot S; Amazit L; Lhomme M; Travers S; DuBow A; Battini S; Boulate G; Namer IJ; Lombes A; Kontush A; Imperiale A; Baudin E; Lombes M
    Oncotarget; 2017 Dec; 8(66):109924-109940. PubMed ID: 29299119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
    Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.
    Hescot S; Slama A; Lombès A; Paci A; Remy H; Leboulleux S; Chadarevian R; Trabado S; Amazit L; Young J; Baudin E; Lombès M
    Endocr Relat Cancer; 2013 Jun; 20(3):371-81. PubMed ID: 23696597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
    Lehmann TP; Wrzesiński T; Jagodziński PP
    Mol Med Rep; 2013 Mar; 7(3):893-900. PubMed ID: 23254310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
    Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
    Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.
    Poli G; Guasti D; Rapizzi E; Fucci R; Canu L; Bandini A; Cini N; Bani D; Mannelli M; Luconi M
    Endocr Relat Cancer; 2013 Aug; 20(4):537-50. PubMed ID: 23722227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Practical use of o,p'DDD in adrenocortical carcinoma].
    Bacchetta J; Droz JP
    Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
    Maher VM; Trainer PJ; Scoppola A; Anderson JV; Thompson GR; Besser GM
    Q J Med; 1992 Sep; 84(305):671-9. PubMed ID: 1480741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.
    Faggiano A; Leboulleux S; Young J; Schlumberger M; Baudin E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):110-3. PubMed ID: 16402938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
    Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V
    Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies.
    Lo Iacono M; Puglisi S; Perotti P; Saba L; Petiti J; Giachino C; Reimondo G; Terzolo M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition.
    Scheidt HA; Haralampiev I; Theisgen S; Schirbel A; Sbiera S; Huster D; Kroiss M; Müller P
    Mol Cell Endocrinol; 2016 Jun; 428():68-81. PubMed ID: 27002491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study.
    Zsippai A; Szabó DR; Tömböl Z; Szabó PM; Eder K; Pállinger E; Gaillard RC; Patócs A; Tóth S; Falus A; Rácz K; Igaz P
    Pharmacogenomics; 2012 Sep; 13(12):1351-61. PubMed ID: 22966885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model.
    Nagy Z; Baghy K; Hunyadi-Gulyás É; Micsik T; Nyírő G; Rácz G; Butz H; Perge P; Kovalszky I; Medzihradszky KF; Rácz K; Patócs A; Igaz P
    Am J Cancer Res; 2015; 5(12):3645-58. PubMed ID: 26885453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
    Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.